Graft-versus-host disease reduction

"Graft-versus-host disease reduction" refers to therapeutic strategies, drugs, or clinical practices aimed at decreasing the incidence, severity, or consequences of graft-versus-host disease (GVHD), a major life-threatening complication of allogeneic hematopoietic stem cell transplantation[1][2][5][6][7]. While many biological targets are implicated in GVHD pathophysiology (including T-cell activation, cytokine signaling pathways, co-stimulatory molecules, and inflammatory mediators), the phrase itself is a treatment objective and not a specific molecule, receptor, enzyme, or gene[1][2][3][5][7][8]. Commonly, drugs or approaches are described by their mechanism of action (e.g., JAK inhibition, T-cell depletion, integrin blockade) that may reduce GVHD, but "graft-versus-host disease reduction" is not a discrete molecular entity and thus cannot be classified as a therapeutic target.